# Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma

> **NCT04437329** · PHASE3 · RECRUITING · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 352 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Docetaxel, nedaplatin, fluorouracil
- **DRUG:** Docetaxel, cisplatin, fluorouracil
- **DRUG:** Nedaplatin
- **DRUG:** Cisplatin
- **RADIATION:** Intensity modulated-radiotherapy

## Key facts

- **NCT ID:** NCT04437329
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 352 (ESTIMATED)
- **Last updated:** 2022-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04437329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04437329, "Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04437329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*